Accessibility Menu
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(LSE) HIK

Market Cap£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)+736%
5 Year-35%
1 Year-10%
1 Month+4%
£16.41
+0.06%
+0.01Today
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeGBX 1,641.002026-08-26
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.03%GBX 1,658.002026-08-19
1 month+4.06%GBX 1,577.002026-07-27
3 month+11.1%GBX 1,477.002026-05-28
Year to date+5.87%GBX 1,550.002025-12-31
1 year-9.84%GBX 1,820.002025-08-26
3 year-22.67%GBX 2,122.002023-08-25
5 year-34.98%GBX 2,524.002021-08-27
Since inception+736.49%GBX 1.962005-11-02

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.63B

Net Income (TTM)

$756.96M

EPS (TTM)

£1.31

P/E Ratio

12.25

Dividend

£0.63

Beta (Volatility)

0.06 (Low)

Price

£16.41

Volume

693,451

Open

£16.41

Previous Close

£16.40

Daily Range

£16.37 - £16.43

52-Week Range

£11.87 - £18.65

Estimated Earnings Date

Feb 25, 2027

HIK News

Why Unilife, Gray Television, and Clovis Oncology Are Today's 3 Best Stocks

Sean WilliamsNov 20, 2013

4 Pharmas With Promising Futures

Brian RichardsJul 31, 2012

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical company engaged in the development, manufacturing, and distribution of a diverse range of generic, branded, and licensed medications. The company operates through three main segments: Injectables, Generics, and Branded, addressing various medical conditions across multiple markets.

Products and Services
  • Injectable medications primarily for hospital use
  • Oral and non-injectable generic pharmaceuticals
  • Branded products for retail and hospital clients
Growth Outlook
  • Revenue of $1.71 billion in Q2 2026, showing strong demand
  • Net income of $221 million in Q2 2026, reflecting profitability
  • Expansion into new markets, enhancing global presence
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.67 billion
  • TTM net profit margin of 11.3%, indicating efficient operations
  • Dividend yield of 3.3%, providing attractive returns
Hikma Pharmaceuticals has established itself as a key player in the pharmaceutical industry, with a comprehensive product portfolio that addresses a wide range of medical needs. The company's focus on injectables and generics positions it well for continued growth, particularly in hospital settings and emerging markets. Recent financial performance highlights a robust revenue stream and solid profitability, making it an appealing option for investors interested in the healthcare sector. The company's commitment to innovation and expansion further supports its potential for long-term success.
AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1H 6AZ, GB

HIK Financials

Key Financial Metrics (TTM)

Gross Margin

40.88%

Operating Margin

19.41%

Net Income Margin

11.31%

Return on Equity

15.05%

Return on Capital

13.81%

Return on Assets

6.59%

Earnings Yield

8.16%

Dividend Yield

3.87%

Payout Ratio

46.65%

Stock Overview

Market Cap

£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

207.23M

Volume

693.45K

Avg. Volume

1.04M

Financials (TTM)

Gross Profit

$2.77B

Operating Income

$1.18B

EBITDA

$1.44B

Operating Cash Flow

$923.55M

Capital Expenditure

-$412.38M

Free Cash Flow

$511.17M

Cash & ST Invst.

$290.50M

Total Debt

$1.97B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,043,384,07210.1%
20232023-12-31USD 2,312,856,07113.2%
20242024-12-31USD 2,447,151,2555.8%
20252025-12-31USD 2,541,182,7523.8%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-312.5%
Q22026-06-300.9%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.68-48.4%
20232023-12-31USD 0.691.3%
20242024-12-31USD 1.2682.9%
20252025-12-31USD 1.379.0%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-40.6%
Q22025-06-3017733.3%
Q42025-12-31-99.3%
Q22026-06-3036.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.71B

+9.2%

Gross Profit

$722.03M

-4.5%

Gross Margin

42.13%

N/A

Market Cap

£3.40BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£357.74K

N/A

Employees

9,500

N/A

Net Income

$221.17M

-2.1%

EBITDA

$478.05M

-4.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$290.50M

+11.7%

Total Debt

$1.97B

+54.2%

Accounts Receivable

$1.13B

+20.3%

Inventory

$1.18B

+26.3%

Long Term Debt

$1.76B

+66.1%

Short Term Debt

$205.06M

-4.6%

Return on Assets

6.59%

N/A

Return on Invested Capital

14.83%

N/A

Free Cash Flow

$46.61M

-63.9%

Operating Cash Flow

$167.62M

-15.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTEC.LConvaTec Group Plc
£2.31+1.14%
HCM.LHUTCHMED (China) Limited
£1.87+4.19%
AGY.LAllergy Therapeutics plc
£0.06-1.79%
BXP.LBeximco Pharmaceuticals Limited
£0.55+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$115.67+0.04%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$48.42-0.05%
IBITiShares Bitcoin Trust
$44.72+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.27+0.02%

Questions About HIK

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at £16.41 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between £11.87 and £18.65.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.19B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $243.86M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 3.87%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services